Actively Recruiting
Study of Cardiovascular Disease Progression After Severe Pneumonia and COVID-19 Lung Infection in Adults
Led by Hellenic Institute for the Study of Sepsis · Updated on 2026-07-06
650
Participants Needed
18
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how pneumonia, including infections like influenza and COVID-19, affects the progression of cardiovascular diseases such as stroke, heart attacks, and pulmonary embolism. The study aims to understand the interactions between the bodys immune response and microbiome during and after pneumonia, and how these affect the risk of cardiovascular and respiratory diseases. This observational study seeks to identify patient subtypes and develop biomarkers to predict treatment responses and disease progression, as well as to explore new therapeutic approaches for cardiovascular diseases related to pneumonia. Participants are grouped into healthy controls, cardiovascular disease risk controls, survivors of severe COVID-19 pneumonia, and survivors of severe community-acquired pneumonia. The study includes collecting blood samples and oropharyngeal swabs to analyze proteins, metabolites, immune cells, and genetic factors. Participants will also undergo tests such as a six-minute walk test, lung function measurements, ECG, heart ultrasound, and cardiopulmonary exercise stress testing, along with symptom questionnaires. These assessments will track the participants health and immune status over time. Participants will be followed for up to 36 months, with primary outcomes including rates of major cardiovascular events at 6 months and poor cardiorespiratory fitness at 36 months. Secondary outcomes cover hospitalizations, respiratory events, quality of life, mental health, metabolic diseases, lung function, and heart performance. The study involves detailed monitoring through clinical tests, questionnaires, and sample analysis to better understand the long-term impacts of pneumonia on cardiovascular health and to identify individuals at risk for complications.
CONDITIONS
Brief Title
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Research Team
P
Prof. Evangelos Giamarellos-Bourboulis
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here